Sangamo Programs On Genomic Medicine | Sangamo Therapeutics, Inc.

Pipeline

NEUROLOGY PIPELINE - WHOLLY OWNED
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Cargo	STAC-BBB
Small Fiber Neuropathy (ST-503)				None	✓	None
Prion Disease (ST-506)				None	✓	✓
Undisclosed neurology target(s)				None	✓	✓

NEUROLOGY PIPELINE - PARTNERED
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Cargo	STAC-BBB
Tauopathies				Genentech	✓	✓
Undisclosed neurology target				Genentech	✓	✓
Undisclosed neurology target				Astellas	None	✓
Undisclosed CNS target				Lilly	None	✓
ALS/FTD				Alexion	✓	None
Huntington's Disease				Takeda	✓	None

OTHER PROGRAMS
Indication	Preclinical	Phase 1/2	Pivotal	Partner	Cargo	STAC-BBB
Fabry Disease (Isaralgagene civaparvovec)				None	✓
Hemophilia A (Giroctogene fitelparvovec)				None	✓

Clinical Programs

Learn more about our Clinical Programs.

Clinical Trials

Learn more about our approach to clinical trials.

Sangamo is conducting several clinical trials to evaluate the safety, tolerability, and potential efficacy of its genomic medicines, some of which we lead and some of which are led by our global pharmaceutical company collaboration partners.

View Clinical Trials

Collaborations

We seek collaborations that can extend or complement our leading genomic medicine capabilities

Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.

Our Partners

Sangamo and Alexion are collaborating for the development and commercialization of therapeutics using our zinc finger transcription factors (ZF-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

Astellas and Sangamo have entered into a worldwide exclusive license agreement allowing Astellas to use Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five neurological disease targets.

Sangamo has a global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases, focused on the tau gene, which is critically involved in Alzheimer’s disease and other tauopathies, as well as a second undisclosed neurology target.

Lilly and Sangamo have entered into a worldwide exclusive license agreement allowing Lilly to use Sangamo’s novel proprietary neurotropic adeno-associated virus (AAV) capsid, STAC-BBB, for up to five potential disease targets of the central nervous system.

Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, has a research evaluation and option agreement with Sangamo to evaluate certain proprietary novel engineered cerebrospinal fluid-administered capsids with enhanced nervous system delivery, generated through Sangamo’s capsid engineering platform, SIFTER.

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our epigenetic regulation platform.

Interested in collaborating with us?

Contact Stephanie Seiler, Head of Business Development and Alliance Management

Contact Stephanie

Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures.